VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Pharma giants are sweating on the results of a federal government request for guidance on adding weight loss drugs to the ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and ...

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

SINGAPORE - Media OutReach Newswire - 27 June 2025 -Imagine a chronic disease affecting more than 600,000 people 1-3 in Singapore — yet often misunderstood, overlooked, or surrounded by stigma. This ...

Raise awareness of obesity as a chronic, multifactorial disease. Reduce stigma and myths that hinder early care. Encourage ...

Novo Nordisk (NVO) is broadening patient access to its FDA-approved weight management drug, Wegovy (semaglutide) 2.4 mg, through a new partnership with WeightWatchers starting ...

Some women may be unaware they’re living with risks for heart disease, kidney disease and metabolic conditions like diabetes, ...

Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy ...